Loading...
XNAS
ORGO
Market cap601mUSD
Dec 05, Last price  
4.74USD
1D
-3.66%
1Q
-5.20%
IPO
-51.63%
Name

Organogenesis Holdings Inc

Chart & Performance

D1W1MN
XNAS:ORGO chart
P/E
698.68
P/S
1.25
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
7.24%
Rev. gr., 5y
13.06%
Revenues
482m
+11.29%
00193,449,000260,981,000338,298,000468,059,000450,893,000433,140,000482,043,000
Net income
861k
-82.59%
-208,698-2,093,913-64,831,000-40,454,00017,234,00094,202,00015,532,0004,945,000861,000
CFO
14m
-54.04%
-10,193,000-562,233-586,604-60,739,000-33,528,0006,801,00061,978,00024,859,00030,917,00014,208,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Avista Public Acquisition Corp. II does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. The company focuses on pursuing businesses in the healthcare industry. Avista Public Acquisition Corp. II was incorporated in 2021 and is based in New York, New York.
URL
https://investors.organogenesis.com
IPO date
Dec 02, 2016
Employees
1,030
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT